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Editorial on the Research Topic
Emerging Mechanisms in Purinergic Signaling: From Cell Biology to Therapeutic Perspectives
Purinergic signaling or purinome is the common name for a complex ensemble of receptors,
extracellular enzymes, and transporters interacting with extracellular ATP and its degradation
products ADP, AMP, and adenosine. It was thanks to the early discovery of professor Burnstock that
ATP, previously tough to exert its function manly intracellularly, could also activate extracellular signals
and to his strong support to the existence of a non-adrenergic non-cholinergic neurotransmission that
purinergic signaling took its first steps. Subsequently, many studies proved that the purinome is involved
not only in neurotransmission but also in the activation of the immune response, carcinogenesis and the
etiopathology of several conditions including but not limited to neuropathic and inflammatory pain,
neurological disorders, cardiovascular, infectious, skeletal, reproductive, and immune system diseases,
alterations of sense organs, airways, skin, muscles, gut, kidney and urinary tract. The purinome includes
the P2X ATP-gated ion channels, metabotropic receptors for ATP (P2Y) and Adenosine (ADORA) but
also ectonucleotidases such as CD39 and CD73 that are responsible for the hydrolysis of ATP to its
derivatives ADP, AMP and adenosine. The intracellular pathways activated by this plethora of receptors
include classical G-proteins coupled c-AMP and inositol triphosphate pathways, but also kinases and
nuclear factors among which MAPK, Akt, PI3K, NF-kB, HIF-1a and NFAT. From a pharmacological
point of view, several potent and selective agonists/antagonists, allosteric modulators, and blocking
antibodies targeting most purinergic receptors and ectonucleotidases are available. Some of these
compounds are currently used in therapy such as the antithrombotics targeting P2Y12 receptor, and
multiple clinical trials are in progress to explore purinergic agents for the treatment of different
neurological, inflammatory, and oncologic diseases among others. Nevertheless, a further research effort
is required to better identify the right drugs or agonist/antagonist combinations and diseases to be
targeted with purinome-centered therapies. This Research Topic aimed to gather new data and opinions
on physio-pathological roles played by the purinome components.
Research articles in this topic include a brief report by Pegoraro et al. that investigates the effect
of P2X7 receptor expression on HHV-6A infection, showing that P2X7 antagonism decreases viral
load. Moreover, the authors demonstrate that P2X7 489C>T polymorphism correlates with HHV-
6A infection in women affected with idiopathic infertility, a condition previously shown to correlate
with HHV-6A infection. These data point to the P2X7 receptor as a potential therapeutic target to
prevent HHV-6 infection and associated infertility.in.org July 2020 | Volume 11 | Article 10221
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consistently reduce the sinoatrial node spontaneous activity
leading to negative cardiac chronotropy. Here, Bragança et al.
demonstrate that activation of P2X4 ionotropic receptors plays a
major role in decreasing the spontaneous activity of the sinoatrial
node while partially offsetting the negative inotropic effect of the
nucleotide in paced rat ventricles. These results strongly suggest
that P2X4 agonists have the potential to became novel well-
tolerated heart-rate lowering drugs with promising benefits in
patients with deteriorated ventricular function.
In the field of neuroprotection, Alves et al. analyze the expression
of P2Y receptors in the cortex following status epilepticus and
determine the impact P2Y1 modulation on cortical damage using a
unilateral mouse model of intra-amygdala kainic acid-induced
status epilepticus. This study extends previous data and confirms
anticonvulsive and neuroprotective properties of P2Y1 antagonism
during status epilepticus, suggesting P2Y1-based treatment as
possible new therapy for drug-resistant status epilepticus.
The ecto-5’-nucleotidase CD73 plays an important role in
regulating vascular permeability and immune cell function. In
this regard, Caiazzo et al. evaluate the effect of CD73 inhibition in
the development of inflammation in the carrageenan-induced
pleurisy model. This study demonstrates that inhibition of CD73
exacerbates the early phase of carrageenan-induced pleurisy by
controlling pleural effusion and polymorphonuclear migration in
vivo and ex vivo. On this basis, the authors suggest that CD73
might represent a valid biomarker for pleural effusion and a
potential target for novel therapeutic interventions.
Another study included in the topic and covering lung
inflammation is that of Santana et al., which investigates the
role of the P2Y12 receptor in silicosis, demonstrating that
inhibition of P2Y12 signaling with clopidogrel prevents silica-
induced changes in lung function, and significantly reduces lung
inflammation, fibrosis, as well as cytokine and nitrite production,
thus preventing lung functional alterations and mortality.
Overviews by purinome experts are also present in this Research
Topic including the article by Stokes et al. that summarizes the current
evidence on the physiological roles of P2X receptors and discuss
whether the use of pharmacological agents enhancing P2X receptor
activity would offer a therapeutic benefit. Based on the advances in
structural information and continued progress in allosteric binding
pocket identification, plus access to the relevant animal models of
disease, the authors convincingly suggest that positive modulation of
P2X receptors will become a new fruitful area of research.
Corciulo and Cronstein give an overview of the purinergic
system in the joint describing the expression and function of
purinome components in the synovia, cartilage, ligament,Frontiers in Pharmacology | www.frontiersin.org 2tendon, and bone and highlighting the therapeutic perspective
of targeting purinergic signaling in this anatomical area.
Similarly, Khalafalla et al. summarize the role of purinergic
receptors in salivary gland function and dysfunction, analyzing
their potential as therapeutic targets to promote saliva flow, prevent
salivary gland inflammation, and enhance tissue regeneration.
In addition, Wei et al. review recent studies that support the role
of Piezo1 channel as an intrinsic mechanosensor to trigger ATP
release and subsequent purinergic receptor activation in several
types of mechanosensitive cell types such as urothelial cells,
endothelial cells, red blood cells, and mesenchymal stem cells.
In conclusion, we believe that the articles presented in this
Research Topic covermultiple aspects of the ongoing research in the
purinergic field and show the difficult task of fully-understanding
the complexity of this ubiquitous signaling cascade.
Finally, we would like to dedicate the issue to the memory of
Professor Geoffrey Burnstock, who recently passed away. He will
always be an example of genius and passion for us and will be
much missed by the scientific community. May he rest in peace
and continue challenging dogmas wherever he is.AUTHOR CONTRIBUTIONS
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